000			nab a22 7a 4500
999			_c17126 _d17126
003			PC17126
005			20221221132636.0
008			221221b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_91208 _aFernández Vázquez, Inmaculada _eAparato Digestivo
245	0	0	_aPeríodo de lead-in y semana 8 como herramientas de predicción de la respuesta en el tratamiento con boceprevir: estudio retrospectivo de la práctica clínica real en España. _h[artículo]
260			_bGastroenterología y hepatología, _c2015
300			_a38(9):517-24.
500			_aFormato Vancouver: Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R et al; en representación del grupo de investigadores del estudio LEAD-IN. Período de lead-in y semana 8 como herramientas de predicción de la respuesta en el tratamiento con boceprevir: estudio retrospectivo de la práctica clínica real en España. Gastroenterol Hepatol. 2015 Nov;38(9):517-24.
501			_aPMID: 25976446
504			_aContiene 16 referencias
520			_aIntroduction: Most discontinuations due to lack of virological response occur during the first few weeks of hepatitis C virus (HCV) triple therapy. Improved knowledge of baseline factors and their correlation with boceprevir decision points may predict treatment success. Methods: An observational, retrospective study was conducted to describe the lead-in period as a clinical decision tool in HCV genotype 1 patients treated with boceprevir. Data were collected from the medical records of 186 consecutive patients distributed across 20 Spanish general hospitals. Results: This study included 171 patients. A total of 80% had fibrosis F3/F4, 74% were previously treated, and 26% were treatment-naïve. After the lead-in period, 54.5% of the patients had a reduction of ≥1 log10; this reduction occurred in 52.5% of those with advanced fibrosis. Boceprevir therapy was started in 94% of the patients. Discontinuations at week 4 were limited to null responders with cirrhosis. The baseline factors associated with virological response at week 4 were IL28B, previous response, and fibrosis score. At week 8, HCV-RNA was undetectable in 48.8% of the patients. The correlation between responses at weeks 8 and 12 was 88%. Conclusion: In the Spanish clinical setting, lead-in was mainly used as a clinical decision point for non-responders with cirrhosis. The good correlation between stopping rules at weeks 8 and 12 could be used to anticipate discontinuation, thus saving adverse events and costs.
710			_9273 _aServicio de Medicina del Aparato Digestivo
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17126.pdf _ySolicitar documento
942			_2ddc _cART _n0